Humanized tumor xenograft mouse models are powerful experimental systems for studying in vivo interactions between human immune cells and human tumors. These models are generated by engrafting both human hematopoietic stem cells and human tumor tissue into immunodeficient mice, such as the NOD/SCID gamma (NSG) strain. In recent years, humanized tumor xenograft mouse models have been integrated into checkpoint inhibitor development programs at many pharmaceutical and biotechnology companies as an indispensable part of the drug development process. As these models have improved, they have been shown to support higher levels of human myeloid-derived cells and regulatory T cells, and have been used successfully in recent studies of anti-PD1 drugs in lung, breast, bladder, and melanoma. Join our experts to hear about the latest research developments utilizing these cutting-edge models.
During this webinar our panelists will:
• Explain the biology of human immune cells and human tumor cells/tissue in the humanized NSG environment
• Describe in vivo responses of human cell-line xenografts and human patient-derived tumor xenografts to checkpoint inhibitor treatments
• Discuss strategies for designing experiments to test combination therapy in vivo
• Answer your questions live during the broadcast!
This Webinar will last for approximately 60 minutes.